BCR and cancer: The BCR-ABL1 oncogene results from the t(9;22)(q34;q11) reciprocal translocation leading to a fusion of a part of the BCR gene on chromosome 9 with the ABL1 gene on chromosome 22.1 The product of BCR-ABL1 expression, the BCR-ABL1 protein, has enhanced tyrosine kinase activity, activates several signaling pathways, and confers growth and proliferation advantages, which are typical for cancer cells.2